Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2346554 | 0.93 | SMN1; SMN2 (0.44) | NOD2NOD1ALDH1A1ELANEPKM | |
| SCHEMBL2350038 | 0.89 | ELANE (0.43) | NOD2NOD1ALDH1A1KMT2AELANE | |
| Hydrochloric Acid SCHEMBL2349568 | 0.85 | ELANE (0.43) | NOD2NOD1ALDH1A1ELANEMAPT | |
| SCHEMBL2349283 | 0.85 | ELANE (0.43) | NOD2NOD1ALDH1A1ELANEPKM | |
| Hydrochloric Acid SCHEMBL2346385 | 0.84 | ELANE (0.42) | NOD2NOD1ALDH1A1ELANEMAPT | |
| SCHEMBL2346957 | 0.83 | ELANE (0.40) | NOD2NOD1ALDH1A1ELANEPKM | |
| SCHEMBL2342085 | 0.82 | ELANE (0.40) | NOD2NOD1ALDH1A1ELANEMAPT | |
| SCHEMBL2345719 | 0.82 | PTGDR (0.41) | NOD2NOD1ALDH1A1MEN1KMT2A | |
| SCHEMBL2348486 | 0.81 | USP2 (0.43) | ELANESMN1; SMN2RAB9A | |
| SCHEMBL2351720 | 0.81 | HTR6 (0.42) | ALDH1A1MEN1KMT2AELANEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| EP-1534268-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060128783-A1 | Tyrosine kinase inhibitors | DINSMORE CHRISTOPHER J | 2006-06-15 | — | — | US | disclosed |
| EP-1534268-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004014300-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128783-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | NOD2 2323/4885NOD1 1661/4885AR 756/4885 |
| US-20080008708-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | NOD2 2323/4885NOD1 1661/4885AR 756/4885 |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, JAK2 | NOD2 2323/4885NOD1 1661/4885AR 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.